Abvc Biopharma Inc

This management proposal seeks shareholder approval for a targeted, one-time increase in the aggregate number of shares reserved under the Company’s Amended and Restated 2016 Equity Incentive Plan so that immediately following the increase the Available Shares equal 15% of the Company’s issued and outstanding common stock as of the meeting date; the Plan’s existing 5% annual evergreen adjustment will resume beginning January 1, 2027. Management justifies the amendment on the grounds that the current pool is insufficient to meet near-term and projected grant needs for employees, contractors, and non-employee directors and that equity awards are necessary to attract and retain key personnel and align interests with shareholders. The amendment is limited in scope—the increase is a one-time adjustment to reach the 15% threshold and does not alter other Plan terms or eliminate the evergreen feature going forward—reducing the scope of shareholder dilution beyond the stated target. The filing quantifies the expected effect using outstanding shares as of the record date (25,423,654 shares), estimating the post-amendment pool at approximately 3,813,548 shares, which permits investors to model dilution and potential option overhang. From a governance perspective, the proposal preserves customary anti-dilution and recycling provisions (forfeited or terminated awards return to the pool) and retains language addressing ISOs and their tax-code limitations. The Board unanimously recommends the amendment; their rationale emphasizes competitive market practice and flexibility for compensation, but shareholders should weigh the dilution impact, the company’s historical grant practices (258,710 options outstanding as of the record date), and any planned grant cadence. Given the company’s stage and reliance on equity to conserve cash, the increase could be commercially sensible, but investors should monitor future grant rates, executive and director award frequency, and disclosure of the use of newly-authorized shares. Finally, approval will enable management to grant meaningful equity incentives promptly without requiring a subsequent shareholder vote, which may accelerate hiring and retention but also concentrates discretion with the board to allocate the newly authorized shares.

This catch-all management proposal authorizes the proxies to vote on any additional matters that may properly come before the annual meeting, providing procedural flexibility to address unforeseen or ministerial issues without reconvening a shareholder vote. Practically, this item is standard in proxy statements and is not a substantive resolution seeking substantive corporate action; it empowers appointed proxies to exercise their judgment if matters not described in the proxy materials are raised at the meeting. While necessary for meeting administration, such authorization can cover a range of matters from procedural adjournments to last-minute ministerial amendments, and therefore carries minimal governance risk in ordinary circumstances. Investors should note that the proxies are instructed to vote according to their best judgment only on matters not on the proxy card; however, because the Board has given voting instructions and a broad mandate to proxies, there is limited shareholder control over unexpected items. The board’s unanimous recommendation for this item is consistent with typical practice, and approval simply ensures efficient meeting logistics. From a risk perspective, shareholders should remain alert to any substantive items introduced at the meeting under this authority, but the company’s representation that there is no other known business reduces the likelihood of controversial unexpected matters. In sum, the item is a routine administrative measure that, if approved, permits orderly conduct of the meeting and enables proxies to address procedural contingencies without additional shareholder action.